Jacques Le Pendu

Jacques Le Pendu


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Veterinary Research
Verified
Journal Article
Open access
PDF file
JAJoana Abrantes
Joana Abrantes
WLWessel van der Loo
Wessel van der Loo
JPJacques Le Pendu
Jacques Le Pendu
Pedro EstevesPedro Esteves
Pedro Esteves
Rabbit haemorrhagic disease virus (RHDV) is a calicivirus of the genus Lagovirus that causes rabbit haemorrhagic disease (RHD) in adult European rabbits (Oryctolagus cuniculus). First described in China in 1984, the virus rapidly spread worldwide and is nowadays considered as endemic in several countries. In Australia and New Zealand where rabbits are pests, RHDV was purposely introduced for rabbit biocontrol. Factors that may have precipitated RHD emergence remain unclear, but non-pathogenic strains seem to pre-date the appearance of the pathogenic strains suggesting a key role for the comprehension of the virus origins. All pathogenic strains are classified within one single serotype, but two subtypes are recognised, RHDV and RHDVa. RHD causes high mortality in both domestic and wild adult animals, with individuals succumbing between 48-72 h post-infection. No other species has been reported to be fatally susceptible to RHD. The disease is characterised by acute necrotising hepatitis, but haemorrhages may also be found in other organs, in particular the lungs, heart, and kidneys due to disseminated intravascular coagulation. Resistance to the disease might be explained in part by genetically determined absence or weak expression of attachment factors, but humoral immunity is also important. Disease control in rabbitries relies mainly on vaccination and biosecurity measures. Such measures are difficult to be implemented in wild populations. More recent research has indicated that RHDV might be used as a molecular tool for therapeutic applications. Although the study of RHDV and RHD has been hampered by the lack of an appropriate cell culture system for the virus, several aspects of the replication, epizootology, epidemiology and evolution have been disclosed. This review provides a broad coverage and description of the current knowledge on the disease and the virus.

1 July 2017 in Journal of General Virology
Verified
Journal Article
Closed access
JPJacques Le Pendu
Jacques Le Pendu
JAJoana Abrantes
Joana Abrantes
SBStéphane Bertagnoli
Stéphane Bertagnoli
JGJean-Sébastien Guitton
Jean-Sébastien Guitton
GGGhislaine Le Gall-Reculé
Ghislaine Le Gall-Reculé
Pedro EstevesPedro Esteves
Pedro Esteves
Lagoviruses belong to the Caliciviridae family. They were first recognized as highly pathogenic viruses of the European rabbit (Oryctolagus cuniculus) and European brown hare (Lepus europaeus) that emerged in the 1970–1980s, namely, rabbit haemorrhagic disease virus (RHDV) and European brown hare syndrome virus (EBHSV), according to the host species from which they had been first detected. However, the diversity of lagoviruses has recently expanded to include new related viruses with varying pathogenicity, geographic distribution and host ranges. Together with the frequent recombination observed amongst circulating viruses, there is a clear need to establish precise guidelines for classifying and naming lagovirus strains. Therefore, here we propose a new nomenclature based on phylogenetic relationships. In this new nomenclature, a single species of lagovirus would be recognized and called Lagovirus europaeus. The species would be divided into two genogroups that correspond to RHDV- and EBHSV-related viruses, respectively. Genogroups could be subdivided into genotypes, which could themselves be subdivided into phylogenetically well-supported variants. Based on available sequences, pairwise distance cutoffs have been defined, but with the accumulation of new sequences these cutoffs may need to be revised. We propose that an international working group could coordinate the nomenclature of lagoviruses and any proposals for revision.

22 January 2021 in Viruses
Verified
Journal Article
Open access
PDF file
JPJacques Le Pendu
Jacques Le Pendu
ABAdrien Breiman
Adrien Breiman
JRJézabel Rocher
Jézabel Rocher
MDMichel Dion
Michel Dion
NRNathalie Ruvoën-Clouet
Nathalie Ruvoën-Clouet
Since the emergence of COVID-19, many publications have reported associations with ABO blood types. Despite between-study discrepancies, an overall consensus has emerged whereby blood group O appears associated with a lower risk of COVID-19, while non-O blood types appear detrimental. Two major hypotheses may explain these findings: First, natural anti-A and anti-B antibodies could be partially protective against SARS-CoV-2 virions carrying blood group antigens originating from non-O individuals. Second, O individuals are less prone to thrombosis and vascular dysfunction than non-O individuals and therefore could be at a lesser risk in case of severe lung dysfunction. Here, we review the literature on the topic in light of these hypotheses. We find that between-study variation may be explained by differences in study settings and that both mechanisms are likely at play. Moreover, as frequencies of ABO phenotypes are highly variable between populations or geographical areas, the ABO coefficient of variation, rather than the frequency of each individual phenotype is expected to determine impact of the ABO system on virus transmission. Accordingly, the ABO coefficient of variation correlates with COVID-19 prevalence. Overall, despite modest apparent risk differences between ABO subtypes, the ABO blood group system might play a major role in the COVID-19 pandemic when considered at the population level.

20 August 2013 in Reviews in Medical Virology
Verified
Journal Article
Closed access
PDF file
NRNathalie Ruvoën‐Clouet
Nathalie Ruvoën‐Clouet
GBGaël Belliot
Gaël Belliot
JPJacques Le Pendu
Jacques Le Pendu

21 May 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
ABAdrien Breiman
Adrien Breiman
NRNathalie Ruvën-Clouet
Nathalie Ruvën-Clouet
JPJacques Le Pendu
Jacques Le Pendu
Enveloped viruses are glycosylated, meaning that their envelope proteins are post-translationally modified by the addition of glycans. Some glycosyltransferases that contribute to terminate glycan chains synthesis are differentially expressed between cell types within or between species, which bears important immunological consequences [1]. A prime example concerns the GGTA1 gene encoding a galactosyltransferase that catalyzes the transfer of a galactose in α1,3 linkage onto subterminal N-acetyllactosamines. This glycosyltransferase is expressed by all mammals except Old World monkeys, apes and humans, due to inactivating mutations that occurred in a common primate ancestor some 20 to 40 million years ago. Consequently, all humans lack the αGal glycan motif and possess natural anti-αGal antibodies generated in response to bacteria of the microbiota that express similar glycans [2]. Likewise, humans lack expression of the N-glycolyl form of sialic acid (NeuGc) due to a pseudogenization event of the CMAH gene that occurred about 2 million years ago. In most other animal species, the orthologous gene encodes the cytidine monophosphate (CMP)-NeuAc hydroxylase that converts NeuAc into NeuGc from the nucleotide form CMP-NeuAc. As a result of our inability to synthesize NeuGc, natural anti-NeuGc are also present in humans (reviewed in [3,4]). Another example concerns the enzymes that are involved in the synthesis of the ABO histo-blood group antigens. The A and B enzymes catalyze the transfer of an N-acetylgalactosamine and a galactose, respectively, in α1,3 linkage on a precursor structure called the H antigen, generating the corresponding A or B antigens. They are encoded by distinct alleles at the ABO locus. The O alleles are null alleles responsible for a lack of transferase, in which case the H antigen remains unchanged. O alleles in the homozygote state confer blood group O, which is characterized by a complete absence of A or B antigens [5]. Under stimulation by bacteria of the microbiota that present glycan motifs similar to either A or B antigens, blood group O people develop so-called "natural" anti-A and anti-B antibodies, whilst blood group A and B individuals develop either anti-B or anti-A antibodies, respectively [6]. Only people of the AB subgroup lack such antibodies. In humans, besides their expression on red blood cells, ABH antigens are widely expressed on many other cell types, including vascular endothelial cells and epithelial cells of many organs [7]. Importantly, the titers of anti-αGal, anti-NeuGc, and anti-A/B antibodies are highly variable between individuals, ranging from 100-to 1000-fold [8,9]. When enveloped viruses are produced by cells expressing these glycan epitopes, they can be effectively neutralized by anti-αGal or anti-A and anti-B antibodies as shown for several animal and human enveloped viruses (reviewed in[2]). Coronavirus S protein trimers are covered by an extensive glycan shield made of N-linked glycans that surrounds the receptor-binding

1 August 2014 in Current Opinion in Virology
Verified
Journal Article
Closed access
JPJacques Le Pendu
Jacques Le Pendu
KNKristina Nyström
Kristina Nyström
NRNathalie Ruvoën-Clouet
Nathalie Ruvoën-Clouet